All News
Despite 30% decrease in mortality over the past 2 decades, the mortality gap remains in psoriasis and #PsA. #ACR20 Abstract #1476 by @Keith_Colaco. @NPF @WCRInstitute @researchuoft @RheumNow @rheum_cat https://t.co/CXTELMJh8P
Lihi Eder lihi_eder ( View Tweet)
#Multimorbidity in #RheumaticDisease: Abs#1466:
-Highly prevalent across RA, PsA, gout & OA
-Highest burden in #gout
Important study highlighting need to recognise burden of MM in #rheumatology patients for holistic optimised management.
#ACR20 @RheumNow
https://t.co/esinnHoUME https://t.co/bApXfx7hOU
Mrinalini Dey DrMiniDey ( View Tweet)
Dr England presents on multimorbidity in RA, PsA, gout, and OA within RISE registry. Highly prevalent in all 4 but most pronounced in gout and RA. Critical to recognise and manage. @rheumnow #ACR20 Abstr#1466 https://t.co/XtwIfJnVXV
Richard Conway RichardPAConway ( View Tweet)
Are there distinct groups of axSpA and PsA patients with peripheral arthritis. This study shows heterogeneous patterns of peripheral involvement and overlap in SpA and PsA groups @RheumNow #ACR20 Abstr#1311 https://t.co/2Q5FH6ZrWm
Dr. Antoni Chan synovialjoints ( View Tweet)
Wanna learn about T2T PsA abstracts from #ACR20? Here are my highlights! @RheumNow https://t.co/0X7FF3rwTz
Dr. Rachel Tate uptoTate ( View Tweet)
SELECT-PsA Phase 3, Placebo, Active controlled trial of Upadacitinib in PsA
1⃣UPA 15mg or 30mg - ⬆️PROs vs. Placebo thru 24wks
2⃣Similar improvement in UPA 15mg vs. 30mg
3⃣Both doses similar or > Adalimumab
@RheumNow #ACR20 Abs#1341 #ACRbest https://t.co/yu9IEX8tf0
Robert B Chao, MD doctorRBC ( View Tweet)
#ACR20👀🔥🔥@AliDuarteMD Population epi revealed:
⭐️Markedly increased SLE incidence
⭐️Drastically increased SLE prevalence
Better epi saves 🫀, saves💰, informs better🧪🔬and💉🩺@RheumNow @LupusOrg @LupusResearch https://t.co/CTzJuB9DVk
Yu (Ray) Zuo RayZuoMD ( View Tweet)
NT-proBNP and TnI predicted cardiovascular events in patients with PsO or PsA. Abs#1328
Do you measure/monitor for cardiovascular disease in your psoriatic patients?
@RheumNow #ACR20
Robert B Chao, MD doctorRBC ( View Tweet)
UPA was efficacious in treating axial symptoms in pts with PsA. #ABS1372 #ACR20 @RheumNow https://t.co/ut6L0jM9WJ https://t.co/6H2N3ap6eI
Dr. Rachel Tate uptoTate ( View Tweet)
Shifting Treatment Paradigms in Psoriatic Arthritis: Dr. Eric Ruderman (@JointMD)
Chicago-based Dr. Eric Ruderman discussed the shifting treatment paradigms in psoriatic arthritis by reviewing abstracts #0504 and #2026 at #ACR20.
https://t.co/jsLkgWG63v https://t.co/h3r2oapOij
Links:
Dr. John Cush RheumNow ( View Tweet)
Two Psoriatic Arthritis Studies: Dr Robert Chao (@doctorRBC)
Dr. Robert Chao discusses abstracts #0375 and #0381 as presented Friday at the #ACR20 annual meeting.
https://t.co/9VpvS1eE2u https://t.co/z2pshtzDeZ
Links:
Dr. John Cush RheumNow ( View Tweet)
So excited to check out RheumNow’s ACR Mid-Meeting Recap live right now with Dr. Jack Cush (@rheumnow), Dr. Arthur Kavanaugh, Dr. Michale Pillinger, and Dr. Bella Mehta! #ACR20
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
This single slide tries to summarise all major phase3 clinical trials in Psoriatic Arthritis 💪
Take your time. The top half looks at joint efficacy. The bottom half for skin efficacy.
#ACR20 https://t.co/FXhJunXNKt
Dr Irwin Lim _connectedcare ( View Tweet)
RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by @Novartis. All content chosen by RheumNow + its Faculty.
Dr. John Cush RheumNow ( View Tweet)
EQUATOR2 52wk extension trial - Filgotinib on enthesitis in PsA pts
1️⃣Clinical resolution of enthesitis at 52wks 77% by LEI and SPARCC
2️⃣Pts who did not respond by wk 16➡️77% and 81% resolution enthesitis by LEI and SPARCC
@RheumNow #ACR20 Abs#0910 https://t.co/mCe32rrAcc
Robert B Chao, MD doctorRBC ( View Tweet)
Health plan claims data appears useful to classify inadequate responders in PsA and should be studied further. #ABS0898 #ACR20 @RheumNow https://t.co/jXBr54Fc6Z https://t.co/fAESyo5Uad
Dr. Rachel Tate uptoTate ( View Tweet)
Neihulizumab, novel immune checkpoint agonistic ab that binds to human CD162 (PSGL-1), thereby preferentially inducing apoptosis in late stage activated T cells. Phase II trial shows efficacy in PsA, further trials to come. #ABS0894 #ACR20 @RheumNow https://t.co/gzf7epPyNd https://t.co/ArLlCyzLxR
Dr. Rachel Tate uptoTate ( View Tweet)
Australian study looking at clinical outcomes following in-class switching vs switching MOA. Rapid effect of IL-17i and JAKi with PsA rated highly. This study highlights ever-growing need for precision medicine based on domain. #ABS09003 #ACR20 @RheumNow https://t.co/7qKH6aw6f0
Dr. Rachel Tate uptoTate ( View Tweet)
BKZ tx improved BASDAI total and single question scores related to fatigue and neck, back and hip pain in pts with PsA. #ABS0906 #ACR20 @RheumNow https://t.co/GzpJfkwvL5 https://t.co/KnJAqAKlqq
Dr. Rachel Tate uptoTate ( View Tweet)
In the search for biomarkers in PsA, interesting study showing absolute lymphocyte count is negatively correlated with cardiovascular disease risk score and red cell distribution width and increases with TNF-Inhibitor Therapy @rheumnow #ACR20 Abstr#878
Dr. Antoni Chan synovialjoints ( View Tweet)
